Last updated: May 25, 2026
Letermovir Suppliers: Who Manufactures and Supplies the Drug Globally, and What Supply Constraints Drive Pricing
Letermovir supply is concentrated around a small set of manufacturing and distribution channels because the product is governed by tightly controlled cGMP manufacturing, specialized cold-chain handling for finished product distribution, and limited validated API and fill-finish capacity. In practice, “suppliers” for letermovir map to (1) API and drug substance manufacturers, (2) finished-dose manufacturers and fill-finish sites, and (3) commercial distribution partners by geography.
However, a complete supplier map requires specific, citable inputs (Orange Book listing or FDA prescribing/labeling manufacturer fields, plus FDA drug establishment registration and/or DMF holders, plus confirmed contract manufacturing and distribution records). Without those exact data points, producing an accurate supplier list would risk listing incorrect entities.
What suppliers make letermovir (API, drug substance, and finished dosage forms)?
Answer: The supplier universe for letermovir is split across API/drug substance manufacture and finished product fill-finish, but the definitive entities are determined by the specific FDA labeling/manufacturer fields and FDA establishment registration records tied to the marketed dosage form(s).
API and drug substance suppliers
Letermovir (CAS 540374-43-5) is typically sourced through DMF-controlled drug substance supply chains. The determinative question for “who supplies letermovir API” is the identity of:
- DMF holder(s) / API manufacturing site(s) for letermovir drug substance
- The labeled “Manufactured for” and “Distributed by” entities on the US and EU product labels
Finished-dose and fill-finish suppliers
For “who supplies letermovir tablets,” the determinative question is:
- The labeled finished-product manufacturer(s)
- The fill-finish site(s) for tablets and any oral formulation variants
Distribution and commercial suppliers by region
For “who supplies letermovir to hospitals and wholesalers,” the determinative question is:
- The “Distributed by” party in each market
- Importer of record or local marketing authorization holder, where applicable
Which companies distribute letermovir in the US, and what do the label ‘Manufactured for’ and ‘Distributed by’ terms show?
Answer: US distribution and manufacturing identities are confirmed by the current US prescribing information and package labeling under the marketed brand. Those label fields typically specify:
- The US labeler (marketing authorization holder)
- The commercial distributor
- The finished-product manufacturer and facility
How many manufacturers supply letermovir, and does multiple sourcing reduce shortages?
Answer: Multiple sourcing lowers single-site risk, but whether letermovir is multiple-sourced depends on validated commercial manufacturing slots across drug substance and finished-dose capacity. Shortage risk is highest when:
- Drug substance relies on a single DMF-controlled production line
- Finished-dose fill-finish is limited to a small number of contract sites
- Regulatory changeovers (process validation updates, site transfers) occur
What patent and exclusivity status affects supplier options for letermovir?
Answer: Letermovir is affected by regulatory exclusivity and patent estate control that can restrict generic entry, but supplier identification is still driven by the actual marketed product’s manufacturing authorizations and registrations, not by exclusivity alone.
What regulatory filings identify letermovir suppliers (FDA DMF, drug establishment registration, and labeling)?
Answer: Supplier identity is determined by:
- FDA drug establishment registration (manufacturing sites by role)
- DMF accessions (drug substance manufacturing and controls)
- FDA application approvals and labeling “Manufactured for / Distributed by”
- EU/National marketing authorization holder and manufacturing authorizations for each dosage form
Key Takeaways
- “Suppliers for letermovir” are best mapped into API/drug substance makers, finished-dose/fill-finish sites, and regional distributors.
- Accurate supplier identification requires the labeled manufacturer/distributor entities and FDA establishment registration and DMF-backed manufacturing records tied to the marketed product.
- Without those exact data points, any named supplier list risks being incorrect.
FAQs
- Who is the letermovir marketing authorization holder in the US?
- Which FDA manufacturing sites produce letermovir tablets?
- Are there multiple DMF holders supplying letermovir drug substance?
- Does cold-chain or controlled handling affect letermovir distribution?
- What are the most common bottlenecks that cause letermovir supply shortages?
References
- (No sources were provided in the input, and no verifiable, citable supplier list can be produced without specific labeling/Orange Book/FDA registration documents.)
